469 related articles for article (PubMed ID: 29570945)
41. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
[TBL] [Abstract][Full Text] [Related]
42. Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib.
Chen F; Luo X; Zhang J; Lu Y; Luo R
Med Oncol; 2010 Sep; 27(3):950-7. PubMed ID: 19830603
[TBL] [Abstract][Full Text] [Related]
43. Serum levels of the cancer-testis antigen POTEE and its clinical significance in non-small-cell lung cancer.
Wang Q; Li X; Ren S; Cheng N; Zhao M; Zhang Y; Li J; Cai W; Zhao C; Cao W; Zhou C
PLoS One; 2015; 10(4):e0122792. PubMed ID: 25860145
[TBL] [Abstract][Full Text] [Related]
44. An Autoantibody Against Human DNA-Topoisomerase I Is a Novel Biomarker for Non-Small Cell Lung Cancer.
Wu WB; Yie SM; Ye SR; Xie K; Zhang JB; Cao M; Chen J; He X; Ma XL; Zhang J
Ann Thorac Surg; 2018 Jun; 105(6):1664-1670. PubMed ID: 29453962
[TBL] [Abstract][Full Text] [Related]
45. Serum Amyloid P-component Level May be a Biomarker for Lung Toxicities and Overall Survival after Thoracic Radiotherapy for Non-small Cell Lung Cancer.
Zhao J; Chi A; Mao R; Hu G; Ji M
Clin Lab; 2016 Nov; 62(11):2183-2190. PubMed ID: 28164664
[TBL] [Abstract][Full Text] [Related]
46. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
[TBL] [Abstract][Full Text] [Related]
47. Relationship between circulating lung-specific X protein messenger ribonucleic acid expression and micrometastasis and prognosis in patients with early-stage nonsmall cell lung cancer.
Cui Y; Wang W; Yao S; Qiu Z; Cong L
J Cancer Res Ther; 2020; 16(7):1641-1647. PubMed ID: 33565511
[TBL] [Abstract][Full Text] [Related]
48. Serum angiopoietin-2 as a clinical marker for lung cancer.
Park JH; Park KJ; Kim YS; Sheen SS; Lee KS; Lee HN; Oh YJ; Hwang SC
Chest; 2007 Jul; 132(1):200-6. PubMed ID: 17505039
[TBL] [Abstract][Full Text] [Related]
49. Serum lemur tyrosine kinase-3: a novel biomarker for screening primary non-small cell lung cancer and predicting cancer progression.
Zhang K; Chen L; Deng H; Zou Y; Liu J; Shi H; Xu B; Lu M; Li C; Jiang J; Wang Z
Int J Clin Exp Pathol; 2015; 8(1):629-35. PubMed ID: 25755755
[TBL] [Abstract][Full Text] [Related]
50. Low plasma miR-25 expression is a favorite prognosis factor in non-small cell lung cancer.
Zhang YL; Zhang ZL; Zhu XB; Xu L; Lu P; Xu M; Liu WJ; Zhang XY; Yao HM; Ye XW
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5251-5259. PubMed ID: 31298376
[TBL] [Abstract][Full Text] [Related]
51. Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer.
Hu LA; Fu Y; Zhang DN; Zhang J
Asian Pac J Cancer Prev; 2013; 14(4):2563-6. PubMed ID: 23725175
[TBL] [Abstract][Full Text] [Related]
52. Serum level of microRNA-147 as diagnostic biomarker in human non-small cell lung cancer.
Chu G; Zhang J; Chen X
J Drug Target; 2016 Aug; 24(7):613-7. PubMed ID: 26581116
[TBL] [Abstract][Full Text] [Related]
53. Prognostic factors in older patients with advanced non-small cell lung cancer in China.
Su Q; Sun YP; Liu YH; Li Z; Yang HY; Sun ZG; Cao BW; Jia JH
Tumori; 2014; 100(1):69-74. PubMed ID: 24675494
[TBL] [Abstract][Full Text] [Related]
54. Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer.
Guo W; Zhang Y; Zhang Y; Shi Y; Xi J; Fan H; Xu S
Int J Mol Med; 2015 Dec; 36(6):1720-6. PubMed ID: 26497897
[TBL] [Abstract][Full Text] [Related]
55. Serum BMP-2 up-regulation as an indicator of poor survival in advanced non-small cell lung cancer patients.
Fei ZH; Yao CY; Yang XL; Huang XE; Ma SL
Asian Pac J Cancer Prev; 2013; 14(9):5293-9. PubMed ID: 24175816
[TBL] [Abstract][Full Text] [Related]
56. A prognostic parameter in advanced non-small cell lung cancer: the ratio of hemoglobin-to-red cell distribution width.
Bozkaya Y; Kurt B; Gürler F
Int J Clin Oncol; 2019 Jul; 24(7):798-806. PubMed ID: 30783810
[TBL] [Abstract][Full Text] [Related]
57. Serum pleiotrophin could be an early indicator for diagnosis and prognosis of non-small cell lung cancer.
Du ZY; Shi MH; Ji CH; Yu Y
Asian Pac J Cancer Prev; 2015; 16(4):1421-5. PubMed ID: 25743809
[TBL] [Abstract][Full Text] [Related]
58. Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer.
Lin Y; Lin WY; Kao CH; Yen KY; Chen SW; Yeh JJ
Anticancer Res; 2012 Nov; 32(11):5087-91. PubMed ID: 23155285
[TBL] [Abstract][Full Text] [Related]
59. Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer.
Hsu WH; Huang CS; Hsu HS; Huang WJ; Lee HC; Huang BS; Huang MH
Ann Thorac Surg; 2007 Feb; 83(2):419-24. PubMed ID: 17257963
[TBL] [Abstract][Full Text] [Related]
60. Serum Biomarkers May Prognosticate Recurrence in Node-Negative, Non-Small Cell Lung Cancers Less Than 4 Centimeters.
Seder CW; Arndt AT; Jordano L; Basu S; Fhied CL; Sayidine S; Chmielewski GW; Gallo K; Liptay MJ; Borgia JA
Ann Thorac Surg; 2017 Nov; 104(5):1637-1643. PubMed ID: 28964418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
